NCT07328490 2026-04-28Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine CancerNational Institutes of Health Clinical Center (CC)Phase 1/2 Withdrawn